CERo Therapeutics Holdings, Inc. CERO
Set alert
0.00 USD 0.00 -11.11%
As of Oct 30, 3:29 PM ET
0.0032 Day range 0.0045
0.004 52-week range 0.121
- YTD
- -94.03%
- 1 year
- -95.79%
- Open
- 0.0045
- Prev close
- 0.0045
- Mkt cap
- 286.52K
- Vol
- 535.72K
- Avg vol
- 612.36K
- EPS
- 40.34
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0032
- High
- 0.0045
- Forward P/E
- 0.00
- Beta
- -0.46
- Short ratio
- 0.29
- Inst. own
- 5.08%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.12674
- 200-d avg
- 0.62712
- 1y target
- 0.00
2Y chart
Events in this range
- Jan 8, 2025Split: 1 for 100
- Jun 13, 2025Split: 1 for 20
Signals (59)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 1 day ago |
| RSI: Oversold | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 5, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 17, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| SMA: Bullish | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 31, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 27, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| RSI: Oversold | Jun 5, 2026 | 4 months ago |
| RSI: Oversold | Jun 1, 2026 | 5 months ago |
| MACD: Sell Signal | May 12, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| MACD: Sell Signal | May 5, 2026 | 5 months ago |
| RSI: Oversold | Mar 5, 2026 | 8 months ago |
| RSI: Oversold | Feb 27, 2026 | 8 months ago |
| RSI: Oversold | Feb 9, 2026 | 8 months ago |
| MACD: Buy Signal | Nov 11, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 10, 2025 | 1 year ago |
| RSI: Oversold | Oct 9, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 22, 2025 | 1 year ago |
| RSI: Oversold | Sep 5, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 28, 2025 | 1 year ago |
| SMA: Bearish | Aug 19, 2025 | 1 year ago |
| SMA: Bullish | Aug 18, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 4, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 24, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 8, 2025 | 1 year ago |
| SMA: Bearish | Jun 18, 2025 | 1 year ago |
| SMA: Bullish | Jun 17, 2025 | 1 year ago |
| RSI: Overbought | Jun 17, 2025 | 1 year ago |
| RSI: Oversold | Jun 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 12, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 10, 2025 | 1 year ago |
| RSI: Oversold | Jun 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 6, 2025 | 1 year ago |
| MACD: Sell Signal | May 12, 2025 | 1 year ago |
| RSI: Oversold | Apr 15, 2025 | 1 year ago |
| RSI: Oversold | Mar 25, 2025 | 1 year ago |
| RSI: Oversold | Mar 21, 2025 | 1 year ago |
| RSI: Oversold | Mar 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 2, 2025 | 1 year ago |
Key statistics
- Market cap
- 7.59M
- Enterprise value
- 20.56M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -1.19
- Beta
- -0.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 14.46M
- Total cash
- 3.65M
- Total debt
- 2.15M
- Return on equity
- 0.00%
- Shares outstanding
- 150.31M
- Short % of float
- 2.08%
- 50-day average
- 0.12674
- 200-day average
- 0.62712
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
CERO Revenue — quarterly 0
CERO Net income — quarterly -5.42M
CERO EPS — quarterly -61.71
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cero.bio
News
- CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
- SRX Global Says UC Davis Activated As Clinical Trial Site For CERTAIN-T, Ongoing Phase 1 Study Evaluating CER-1236 In Patients With Hematologic Malignancies Being Conducted By CERo Therapeutics
- CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers
- CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
- CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
- CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
- CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
- CERo Therapeutics Provides Shareholder Update
- CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
- CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
Your note
Sign in to keep a note on CERO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ATWOOD BRIAN G | Director | Conversion of Exercise of derivative security | Sep 24, 2024 | 0 |
| EHRLICH CHRISTOPHER B | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 24, 2024 | 5,795,410 |
| LAPORTE KATHLEEN D | Director | Conversion of Exercise of derivative security | Sep 24, 2024 | 0 |
| SLOAN STUART M | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 24, 2024 | 0 |
| YK BIOVENTURES OPPORTUNITIES GP I, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 12, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Arch Venture Management, Llc | 0.96% | 1,444,296 | 72.94K | Sep 29, 2024 |
| Avantax Planning Partners, Inc. | 0.91% | 1,361,130 | 68.74K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.10% | 157,445 | 7.95K | Sep 29, 2024 |
| Selkirk Management Llc | 0.08% | 121,040 | 6.11K | Sep 29, 2024 |
| HRT Financial LP | 0.05% | 79,562 | 4.02K | Sep 29, 2024 |
| Fifth Lane Capital, LP | 0.05% | 76,593 | 3.87K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.10% | 144,145 | 7.28K | Oct 30, 2024 |